Expert recommendations for the laboratory diagnosis of MPS VI

T. Wood, O. A. Bodamer, M. G. Burin, V. D'Almeida, M. Fietz, R. Giugliani, S. M. Hawley, C. J. Hendriksz, W. L. Hwu, D. Ketteridge, Z. Lukacs, N. J. Mendelsohn, N. Miller, M. Pasquali, A. Schenone, K. Schoonderwoerd, B. Winchester, P. Harmatz

Research output: Contribution to journalArticle

26 Scopus citations

Abstract

Mucopolysaccharidosis VI (MPS VI) is a lysosomal storage disease caused by a deficiency of N-acetylgalactosamine 4-sulfatase (arylsulfatase B, ASB). This enzyme is required for the degradation of dermatan sulfate. In its absence, dermatan sulfate accumulates in cells and is excreted in large quantities in urine. Specific therapeutic intervention is available; however, accurate and timely diagnosis is crucial for maximal benefit. To better understand the current practices for diagnosis and to establish diagnostic guidelines, an international MPS VI laboratory diagnostics scientific summit was held in February of 2011 in Miami, Florida.The various steps in the diagnosis of MPS VI were discussed including urinary glycosaminoglycan (uGAG) analysis, enzyme activity analysis, and molecular analysis. The following conclusions were reached. Dilute urine samples pose a significant problem for uGAG analysis and MPS VI patients can be missed by quantitative uGAG testing alone as dermatan sulfate may not always be excreted in large quantities. Enzyme activity analysis is universally acknowledged as a key component of diagnosis; however, several caveats must be considered and the appropriate use of reference enzymes is essential. Molecular analysis supports enzyme activity test results and is essential for carrier testing, subsequent genetic counseling, and prenatal testing.Overall the expert panel recommends caution in the use of uGAG screening alone to rule out or confirm the diagnosis of MPS VI and acknowledges enzyme activity analysis as a critical component of diagnosis. Measurement of another sulfatase enzyme to exclude multiple sulfatase deficiency was recommended prior to the initiation of therapy. When feasible, the use of molecular testing as part of the diagnosis is encouraged. A diagnostic algorithm for MPS VI is provided.

Original languageEnglish (US)
Pages (from-to)73-82
Number of pages10
JournalMolecular Genetics and Metabolism
Volume106
Issue number1
DOIs
StatePublished - May 1 2012

Keywords

  • Algorithm
  • Arylsulfatase B
  • Diagnosis
  • Glycosaminoglycan
  • Maroteaux-Lamy syndrome
  • MPS VI

ASJC Scopus subject areas

  • Biochemistry
  • Molecular Biology
  • Genetics
  • Endocrinology
  • Endocrinology, Diabetes and Metabolism

Fingerprint Dive into the research topics of 'Expert recommendations for the laboratory diagnosis of MPS VI'. Together they form a unique fingerprint.

  • Cite this

    Wood, T., Bodamer, O. A., Burin, M. G., D'Almeida, V., Fietz, M., Giugliani, R., Hawley, S. M., Hendriksz, C. J., Hwu, W. L., Ketteridge, D., Lukacs, Z., Mendelsohn, N. J., Miller, N., Pasquali, M., Schenone, A., Schoonderwoerd, K., Winchester, B., & Harmatz, P. (2012). Expert recommendations for the laboratory diagnosis of MPS VI. Molecular Genetics and Metabolism, 106(1), 73-82. https://doi.org/10.1016/j.ymgme.2012.02.005